Varicella-zoster virus encephalitis and vasculopathy in a patient treated with fingolimod

Neurology

Volumn 79, Issue 19, 2012, Pages 2002-2004

  Ratchford, John N ^a   Costello, Kathleen ^a   Reich, Daniel S ^a,b   Calabresi, Peter A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ETIRACETAM; FINGOLIMOD; GADOLINIUM; NATALIZUMAB; PREDNISONE; VALACICLOVIR;

ADULT; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; COMA; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; REHABILITATION CARE; REVIEW; SEIZURE; TREATMENT RESPONSE; VARICELLA ZOSTER VIRUS; VASCULAR DISEASE; VASCULITIS; VIRUS ENCEPHALITIS;

EID: 84871255428     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182735d00     Document Type: Article

References (6)

1. Nagel MA, Cohrs RJ, Mahalingam R, et al. The varicella zoster virus vasculopathies: clinical, CSF, imaging, and virologic features. Neurology 2008;70:853-860.
2. Gilenya Prescribing Information. Basel, Switzerland: Novartis; 2012.
3. Calabresi PA, Radue E-W, Goodin D, et al. Efficacy and safety of fingolimod in patients with relapsing-remitting multiple sclerosis (RRMS): results from an additional 24-month double-blind, placebo-controlled study (FREEDOMS II Study). Neurology 2012. Abstract. Emerging Science 015.
4. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-415.
5. Kappos L, Radue EW, O'Connor P, et al. A placebocontrolled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401.
6. Novartis press release, December 15, 2011. Available at: http://www.novartis.com/newsroom/media-releases/en/2011/1571509.shtml. Accessed March 29, 2012.